Skip to main content
CML-CP: Imatinib discontinuation feasible in children with sustained DMR for at least 2 years
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
CML-CP: Imatinib discontinuation feasible in children with sustained DMR for at least 2 years
User login
Username
Password
Reset your password
Type
Lead
score
Edit Tags